📉 Financial Breakdown - Kya Kehte Hain Numbers?
Abhi details mein dekhte hain ki ye numbers aaye kaise. Pichhle saal isi period mein company ₹29.3 crore ke loss mein thi, aur ab woh ₹67.4 crore profit mein aa gayi hai! Per share earning bhi ₹-2.1 se sudhar kar ₹4.9 ho gayi hai.
Revenue ki baat karein toh, 10.4% badhkar ₹1,718 crore ho gaya hai. Lekin, EBITDA thoda gira hai 18.7% se ₹182 crore pe, aur Adjusted EBITDA margin bhi 14.0% ho gaya 16.4% se. Ye sign hai ki company invest kar rahi hai.
Aur Q3 ki baat karein toh, revenue 7.5% badhkar ₹583.8 crore hua, aur net profit toh 86.35% boom kar ₹32.63 crore pe pahunch gaya! Lekin haan, Q3 mein bhi EBITDA margin thoda kam hokar 9.7% ho gaya 11.9% se.
🤔 Toh Investor ke liye Iska Matlab Kya Hai?
Simple words mein, company abhi global growth par bahut paisa laga rahi hai. Naye global growth centres bana rahi hai, innovation mein invest kar rahi hai. Isi wajah se short-term mein margins thode dab rahe hain aur EBITDA kam dikh raha hai. Lekin badi baat ye hai ki inhone US mein apna pehla customer order pakad liya hai! Ye unke US expansion ke liye ek bada step hai, jo future mein badi growth la sakta hai. Toh investors ko ye dekhna hoga ki ye investments long-term mein company ko kahan le jaati hain aur kya ye profit ko sustain kar paate hain.
🚀 Aage Ka Plan Aur Thoda Risk
Company ka kehna hai ki woh apne global centres ko aur mazboot karenge, capacity badhayenge aur R&D mein invest karna jari rakhenge, future growth ke liye. US CDC mein order milna sach mein ek badi success hai aur dikhata hai ki market mein entry ho gayi hai.
Lekin, ek chota sa risk ye hai ki in sab growth plans ke liye shayad thoda debt bhi badh sakta hai. CFO ne kaha hai ki woh financial discipline, capital structure, working capital aur cash conversion par dhyan denge, toh dekhte hain kaise manage karte hain. Long-term mein focus global expansion aur R&D par hi hai, aur ye dekhna interesting hoga ki isse company kitni aage badhti hai.